Free Trial
NASDAQ:LXRX

Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis

Lexicon Pharmaceuticals logo
$1.15 +0.02 (+1.77%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.43%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)

Key Stats

Today's Range
$1.10
$1.15
50-Day Range
$0.73
$1.35
52-Week Range
$0.28
$2.18
Volume
1.76 million shs
Average Volume
8.38 million shs
Market Capitalization
$417.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.23
Consensus Rating
Moderate Buy

Company Overview

Lexicon Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

LXRX MarketRank™: 

Lexicon Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 536th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lexicon Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lexicon Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Lexicon Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.66) to ($0.45) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lexicon Pharmaceuticals is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lexicon Pharmaceuticals is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lexicon Pharmaceuticals has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lexicon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    8.65% of the float of Lexicon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Lexicon Pharmaceuticals has recently decreased by 7.36%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lexicon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Lexicon Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.65% of the float of Lexicon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Lexicon Pharmaceuticals has recently decreased by 7.36%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lexicon Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Lexicon Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    7 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.90% of the stock of Lexicon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lexicon Pharmaceuticals' insider trading history.
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LXRX Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
See More Headlines

LXRX Stock Analysis - Frequently Asked Questions

Lexicon Pharmaceuticals' stock was trading at $0.7385 at the beginning of the year. Since then, LXRX stock has increased by 53.7% and is now trading at $1.1350.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Wednesday, August, 6th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. The biopharmaceutical company earned $28.87 million during the quarter, compared to analyst estimates of $4.87 million. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative trailing twelve-month return on equity of 83.63%.
Read the conference call transcript
.

Lexicon Pharmaceuticals' top institutional investors include Geode Capital Management LLC (0.66%), Monaco Asset Management SAM (0.15%), Invesco Ltd. (0.12%) and Compagnie Lombard Odier SCmA (0.09%). Insiders that own company stock include International SCA Artal, Raymond Debbane, Lonnel Coats, Jeffrey L Wade and Wendy Mcdermott.
View institutional ownership trends
.

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA).

Company Calendar

Last Earnings
8/06/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CIK
1062822
Employees
140
Year Founded
1995

Price Target and Rating

High Price Target
$6.00
Low Price Target
$1.00
Potential Upside/Downside
+189.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$200.40 million
Net Margins
-206.43%
Pretax Margin
-206.43%
Return on Equity
-83.63%
Return on Assets
-42.22%

Debt

Debt-to-Equity Ratio
0.43
Current Ratio
4.16
Quick Ratio
4.16

Sales & Book Value

Annual Sales
$31.08 million
Price / Sales
13.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.36 per share
Price / Book
3.10

Miscellaneous

Outstanding Shares
363,400,000
Free Float
312,887,000
Market Cap
$405.19 million
Optionable
Optionable
Beta
1.17

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:LXRX) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners